

# Zika virus infection weekly report

## 21 September 2016

This report summarises confirmed and probable Zika virus infection notifications for the previous week (14–20 September 2016) and cumulative cases for 2016. Cases that were still under investigation are not included. The case classification used in this report is specified on the last page.

The report incorporates the distribution of cases by sex, age and country(ies) travelled to during the incubation period for the disease. No further details on individual cases will be released.

Data in this weekly update is based on data recorded on EpiSurv by public health service staff as at 0715 hours 21 September 2016. Changes made to EpiSurv data after this date will not be reflected in this report. The numbers presented may be further updated and should be regarded as provisional.

### Previous week (14–20 September 2016)

**Table 1. Zika virus infection (confirmed and probable) cases notified in New Zealand by sex, age group and case status, 14–20 September 2016**

Sex	Age group (years)	Number of cases		Total cases
		Confirmed	Probable	
<b>Female</b>	<1			0
	1–4			0
	5–14			0
	15–24			0
	25–44			0
	45–64			0
	65+	1		1
<b>Female total</b>		<b>1</b>	<b>0</b>	<b>1</b>
<b>Male</b>	<1			0
	1–4			0
	5–14			0
	15–24			0
	25–44			0
	45–64			0
	65+	1		1
<b>Male total</b>		<b>1</b>	<b>0</b>	<b>1</b>
<b>Total</b>		<b>2</b>	<b>0</b>	<b>2</b>

**Table 2. Overseas travel information for Zika virus infection (confirmed) cases notified in New Zealand, 14–20 September 2016**

Country travelled to during the incubation period for the disease	Number of confirmed cases <sup>1</sup>
Trinidad and Tobago	2
USA <sup>2</sup>	2

<sup>1</sup> Cases may have visited more than one country or may not have specified the country.

<sup>2</sup> Cases had also travelled to Trinidad and Tobago and had an onset of symptoms prior to travelling to the USA.

## Year to date (1 January–20 September 2016)

**Table 3. Zika virus infection (confirmed and probable) cases notified in New Zealand by sex, age group and case status, 1 January–20 September 2016**

Sex	Age group (years)	Number of cases <sup>1</sup>		Total cases
		Confirmed	Probable	
<b>Female</b>	<1			0
	1–4	1		1
	5–14	2		2
	15–24	15		15
	25–44	29	2	31
	45–64	17		17
	65+	3		3
<b>Female total</b>		<b>67</b>	<b>2</b>	<b>69</b>
<b>Male</b>	<1			0
	1–4			0
	5–14	1		1
	15–24	3	1	4
	25–44	8	2	10
	45–64	11	1	12
	65+	3		3
<b>Male total</b>		<b>26</b>	<b>4</b>	<b>30</b>
<b>Total</b>		<b>93</b>	<b>6</b>	<b>99</b>

<sup>1</sup> Includes cases that in previous reports were still under investigation and have since become confirmed or probable cases.

**Table 4. Overseas travel information for Zika virus infection (confirmed) cases notified in New Zealand, 1 January–20 September 2016**

Country travelled to during the incubation period for the disease	Number of confirmed cases <sup>1,2</sup>
Tonga	53
Samoa	22
Fiji	9
American Samoa	2
Australia <sup>3</sup>	1
Colombia	1
Indonesia	1
Nicaragua	1
Papua New Guinea	1
Trinidad and Tobago	2
United States of America <sup>4</sup>	3
Venezuela	1
No overseas travel	1


<sup>1</sup> Cases may have visited more than one country or may not have specified the country.

<sup>2</sup> Includes cases that in previous reports were still under investigation and have since become confirmed cases.

<sup>3</sup> Transit only case had also travelled to Papua New Guinea.

<sup>4</sup> Cases had also travelled to Nicaragua or Trinidad and Tobago and had an onset of symptoms prior to travelling to the USA.

**Figure 1. Zika virus infection (confirmed) cases notified in New Zealand by EpiSurv surveillance week (n=93), 1 January–20 September 2016**



\* Incomplete surveillance week 17/09/2016–20/09/2016 only

## Case classification for arboviral disease notification in New Zealand

<b>Confirmed</b>	<p>A clinically compatible illness that is laboratory confirmed.</p> <p><b>Laboratory confirmation requires</b> at least one of the following:</p> <ul style="list-style-type: none"> <li>• isolation of the virus</li> <li>• detection of arbovirus nucleic acid</li> <li>• detection of arbovirus-specific IgM</li> <li>• IgG seroconversion</li> <li>• a significant increase (four-fold or greater) in antibody titres to specific arbovirus.</li> </ul>
<b>Probable</b>	A clinically compatible illness in a person who has come from an endemic area.
<b>Under investigation</b>	A case that has been notified, but information is not yet available to classify it as probable or confirmed.
<b>See:</b>	<a href="http://www.health.govt.nz/system/files/documents/publications/cd-manual-arboviral-diseases-may2012.pdf">http://www.health.govt.nz/system/files/documents/publications/cd-manual-arboviral-diseases-may2012.pdf</a>



THE SCIENCE  
BEHIND THE  
TRUTH

**INSTITUTE OF ENVIRONMENTAL  
SCIENCE AND RESEARCH LIMITED**

▀ **Kenepuru Science Centre**  
34 Kenepuru Drive, Kenepuru, Porirua 5022  
PO Box 50348, Porirua 5240  
New Zealand  
T: +64 4 914 0700 F: +64 4 914 0770

▀ **Mt Albert Science Centre**  
120 Mt Albert Road, Sandringham, Auckland 1025  
Private Bag 92021, Auckland 1142  
New Zealand  
T: +64 9 815 3670 F: +64 9 849 6046

▀ **NCBID – Wallaceville**  
66 Ward Street, Wallaceville, Upper Hutt 5018  
PO Box 40158, Upper Hutt 5140  
New Zealand  
T: +64 4 529 0600 F: +64 4 529 0601

▀ **Christchurch Science Centre**  
27 Creyke Road, Ilam, Christchurch 8041  
PO Box 29181, Christchurch 8540  
New Zealand  
T: +64 3 351 6019 F: +64 3 351 0010

**[www.esr.cri.nz](http://www.esr.cri.nz)**